437 related articles for article (PubMed ID: 22999942)
21. Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemia.
Hsieh YY; Hong YC; Hsiao LT; Yu YB; Liu JH; Gau JP; Lin HN; Hsu YN; Chiou TJ; Chen PM; Tzeng CH; Liu CY
Eur J Haematol; 2011 Mar; 86(3):237-45. PubMed ID: 21155895
[TBL] [Abstract][Full Text] [Related]
22. Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study.
Sisler IY; Koehler E; Koyama T; Domm JA; Ryan R; Levine JE; Pulsipher MA; Haut PR; Schultz KR; Taylor DS; Frangoul HA
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1620-7. PubMed ID: 19896086
[TBL] [Abstract][Full Text] [Related]
23. Superior transplantation outcomes of 8/8-matched unrelated donors as well as matched siblings to autologous transplantation for acute myeloid leukemia with intermediate cytogenetics in first remission.
Cho BS; Kim JH; Yoon JH; Shin SH; Yahng SA; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
Eur J Haematol; 2013 May; 90(5):365-74. PubMed ID: 23414524
[TBL] [Abstract][Full Text] [Related]
24. Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR.
Michelis FV; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Lambie A; Lipton JH; Loach D; Messner HA
Bone Marrow Transplant; 2013 Nov; 48(11):1450-5. PubMed ID: 23686095
[TBL] [Abstract][Full Text] [Related]
25. Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics.
Yamasaki S; Yoshimoto G; Ogawa R; Aoki K; Higuchi M; Harada N; Arima F; Kondo S; Matubara F; Takahashi T; Uike N; Miyamoto T; Okamura S; Akashi K;
Ann Hematol; 2015 Jul; 94(7):1159-65. PubMed ID: 25704584
[TBL] [Abstract][Full Text] [Related]
26. Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission.
Vydra J; Šálek C; Schwarz J; Žák P; Novák J; Petečuková V; Pecherková P; Mayer J; Cetkovský P; Ráčil Z
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):106-113. PubMed ID: 29289481
[TBL] [Abstract][Full Text] [Related]
27. Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission.
Lv M; Wang Y; Chang YJ; Zhang XH; Xu LP; Jiang Q; Jiang H; Lu J; Chen H; Han W; Wang FR; Wang JZ; Chen Y; Yan CH; Zhang YY; Sun YQ; Mo XD; Zhu HH; Jia JS; Zhao T; Wang J; Liu KY; Huang XJ
Clin Cancer Res; 2019 Mar; 25(6):1737-1748. PubMed ID: 30478089
[TBL] [Abstract][Full Text] [Related]
28. Impact of pretransplantation risk factors on post transplantation outcome of patients with acute myeloid leukemia in remission after haploidentical hematopoietic stem cell transplantation.
Wang Y; Liu DH; Liu KY; Xu LP; Zhang XH; Han W; Chen H; Chen YH; Huang XJ
Biol Blood Marrow Transplant; 2013 Feb; 19(2):283-90. PubMed ID: 23063629
[TBL] [Abstract][Full Text] [Related]
29. A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission.
Kurosawa S; Yamaguchi T; Miyawaki S; Uchida N; Kanamori H; Usuki K; Yamashita T; Watanabe M; Yakushiji K; Yano S; Nawa Y; Taguchi J; Takeuchi J; Tomiyama J; Nakamura Y; Miura I; Kanda Y; Takaue Y; Fukuda T
Blood; 2011 Feb; 117(7):2113-20. PubMed ID: 21106987
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.
Röllig C; Bornhäuser M; Kramer M; Thiede C; Ho AD; Krämer A; Schäfer-Eckart K; Wandt H; Hänel M; Einsele H; Aulitzky WE; Schmitz N; Berdel WE; Stelljes M; Müller-Tidow C; Krug U; Platzbecker U; Wermke M; Baldus CD; Krause SW; Stölzel F; von Bonin M; Schaich M; Serve H; Schetelig J; Ehninger G
J Clin Oncol; 2015 Feb; 33(5):403-10. PubMed ID: 25547501
[TBL] [Abstract][Full Text] [Related]
31. Autologous hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission: a meta-analysis of randomized trials.
Wang J; Ouyang J; Zhou R; Chen B; Yang Y
Acta Haematol; 2010; 124(2):61-71. PubMed ID: 20616541
[TBL] [Abstract][Full Text] [Related]
32. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
33. Autologous blood stem cell transplantation for acute myeloblastic leukemia in first complete remission. Intensification therapy before transplantation does not prolong disease-free survival.
de la Rubia J; Sanz GF; Martín G; Martínez J; Cervera J; Solves P; Jiménez C; Arnao M; Vicente A; Jarque I; Sempere A; Sanz MA
Haematologica; 1999 Feb; 84(2):125-32. PubMed ID: 10091410
[TBL] [Abstract][Full Text] [Related]
34. Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
Labouré G; Dulucq S; Labopin M; Tabrizi R; Guérin E; Pigneux A; Lafarge X; Leguay T; Bouabdallah K; Dilhuydy MS; Duclos C; Lascaux A; Marit G; Mahon FX; Boiron JM; Milpied N; Vigouroux S
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1845-50. PubMed ID: 22766221
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Parameters of Acute Myeloid Leukaemia at Presentation.
Jahic A; Iljazovic E; Hasic S; Arnautovic AC; Sabitovic D; Mesanovic S; Sahovic H; Simendic V
Med Arch; 2017 Feb; 71(1):20-24. PubMed ID: 28428668
[TBL] [Abstract][Full Text] [Related]
36. Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.
Pagel JM; Othus M; Garcia-Manero G; Fang M; Radich JP; Rizzieri DA; Marcucci G; Strickland SA; Litzow MR; Savoie ML; Spellman SR; Confer DL; Chell JW; Brown M; Medeiros BC; Sekeres MA; Lin TL; Uy GL; Powell BL; Bayer RL; Larson RA; Stone RM; Claxton D; Essell J; Luger SM; Mohan SR; Moseley A; Erba HP; Appelbaum FR
JCO Oncol Pract; 2020 Jun; 16(6):e464-e475. PubMed ID: 32048933
[TBL] [Abstract][Full Text] [Related]
37. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.
Brunet S; Labopin M; Esteve J; Cornelissen J; Socié G; Iori AP; Verdonck LF; Volin L; Gratwohl A; Sierra J; Mohty M; Rocha V
J Clin Oncol; 2012 Mar; 30(7):735-41. PubMed ID: 22291086
[TBL] [Abstract][Full Text] [Related]
38. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.
Kalaycio M; Advani A; Pohlman B; Sekeres M; Tripp B; Rybicki L; Sobecks R
Am J Hematol; 2008 Nov; 83(11):831-4. PubMed ID: 18756545
[TBL] [Abstract][Full Text] [Related]
39. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW
Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688
[TBL] [Abstract][Full Text] [Related]
40. Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types.
Yoon JH; Kim HJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Oncotarget; 2017 Jun; 8(25):41590-41604. PubMed ID: 28206975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
